EUVIMEDEUVIMED entdecken
Crossref

From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?

Keith L. Carson

BioProcessing Journal · 28.07.2026 · 4

DOI: 10.12665/j124.carson ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioProcessing Journal, online erschienen am 28.07.2026. Verfasst von Keith L. Carson.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

I’ve seen little to tell me the major biopharma firms, or the larger supply firms, have learned anything. They’re stuck on the concepts of slashing vital resources—such as R&D and capacity—to “do deals” plus pay executive bonuses, investment bankers, and hordes of attorneys. As a result, we’ve seen a burgeoning of Business-to-Business (B2B) meetings where the talks are geared toward selling companies and acquisition services. So we continue to see these large firms hoarding cash, acquiring companies, and cutting strategic resources...

Zitieren

APA

Carson, K. L. (2026). From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?. BioProcessing Journal, 4. https://doi.org/10.12665/j124.carson

Vancouver

Carson KL. From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?. BioProcessing Journal. 2026:4. doi:10.12665/j124.carson

BibTeX
@article{Carson2026,
  author = {Carson, Keith L.},
  title = {From the Editor-in-Chief: Where's the Value in These Never-Ending M&As?},
  journal = {BioProcessing Journal},
  year = {2026},
  pages = {4},
  doi = {10.12665/j124.carson}
}
Kostenlos starten →